Study Finds Psilocybin Use Lowers Odds of Being

New Post Public Reply Private Reply Replies (0) Message Board
NetworkNewsWire
301
Study Finds Psilocybin Use Lowers Odds of Being Arrested

A new study has linked the use of psilocybin with a reduction in the likelihood of an individual engaging in criminal behavior. Psilocybin is the active compound found in hallucinogenic mushrooms.

Harvard University clinical psychology PhD candidate Grant Jones, the author of the study, stated that his interest in psychedelics grew as the substances gained more attention because of their treatment potential, having demonstrated that they could be used to relieve a number of mental health conditions. Jones explained that the purpose of the research was to investigate the relationship between criminality and psychedelics using population-based survey data, because not many studies on this had been done.

The researchers were especially interested in finding the link between reduced criminal behavior and the use of psychedelics, explaining that prior studies only looked into the link between crime arrests and classic psychedelics as a group.

For their own study, the researchers sought to investigate the link between crime arrest outcomes and a number of classic psychedelic compounds, including mescaline, peyote, LSD and psilocybin. They used data obtained from the National Survey on Drug Use and Health survey, which gathers information on mental health outcomes and drug use in the United States annually.

The researchers conducted an analysis of this data, which comprised of a sample made up of more than 211,000 adults who filled out the survey in the period between 2015 and 2019. The survey asked respondents if they had been arrested for burglary, larceny, robbery, motor vehicle theft, serious violent offenses, assault/battery, possession of stolen goods, fraud, vandalism, public drunkenness, drug possession/sale and DUIs, among other crimes.

The researchers discovered that individuals who used psilocybin reported lower odds of being arrested for DUIs, serious violence, assault/battery, robbery, burglary, larceny and miscellaneous crimes. The use of peyote was also linked to lower rates of being arrested for DUIs and motor vehicle theft.

The researchers also found that LSD was the most commonly used drug, noting that its use wasn’t associated with criminal arrests. However, the use of marijuana, cocaine and heroin was linked to significantly higher chances of criminal arrests.

The study’s findings offer evidence that the use of psilocybin corresponds to lower chances of criminal arrest, even after accounting for a number of demographic factors, including level of education, class and race. In their report, the researchers highlight that the findings should be viewed as a preliminary link between lower chances of criminal arrests and the use of psilocybin, noting that more research is needed to better understand this association.

The study’s findings were reported in the “Journal of Psychopharmacology.”

The findings of this study aren’t surprising to a large extent, given the many beneficial effects being documented about psilocybin and how companies such as Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) are devoting significant time and funds towards developing therapeutic products from this and other psychedelic compounds in a bid to address the treatment needs of people battling addiction and other mental health issues.

NOTE TO INVESTORS: The latest news and updates relating to Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) are available in the company’s newsroom at https://ibn.fm/MYCOF

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer


Mydecine Innovations Group Inc (MYCOF) Stock Research Links

MYCOF Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

iCapital Enhances Portfolio Solutions For Global Investors

Updated Category News Views 267

iCapital Enhances Portfolio Construction Tools for Investors iCapital, a leading global fintech platform, has introduced significant enhancements to its innovative portfolio construction tool, iCapital Architect. This advanced platform is designed to simplify the integration of alternative investments into traditional portfolio strategies. Financial advisors gain access...

Continue Reading
Market Adaptability: S&P 500 Faces Correction Ahead

Updated Category News Views 210

Understanding Recent Market Movements The market experienced a turbulent session recently, sending investors into a state of caution. This volatility was significantly influenced by renewed discussions around tariffs impacting trade relationships, particularly involving technology and manufacturing sectors. The Impact of Tariffs on the Market Former President Trump's...

Continue Reading
Performance Systems Integration Merges with Summit Fire & Security

Updated Category News Views 177

Performance Systems Integration Merger with Summit Fire & Security Performance Systems Integration (PSI), recognized as the leading fire and life safety solutions provider in the Pacific Northwest, has completed a merger with Summit Fire & Security LLC, which is a subsidiary of SFP Holding, Inc. This merger marks a significant collaboration that aims to enhance the safety...

Continue Reading
Candel Therapeutics Shares Optimistic Findings on CAN-3110

Updated Category News Views 159

Revealing Interim Results from Candel Therapeutics NEEDHAM, Mass. — Candel Therapeutics, Inc. (Nasdaq: CADL), a biopharmaceutical company dedicated to advancing biological immunotherapies to combat cancer, has announced noteworthy interim data stemming from its ongoing phase 1b clinical trial of CAN-3110 (linoserpaturev) targeting recurrent glioblastoma. This...

Continue Reading
Supernus Pharmaceuticals Reaches New Heights with Strong Growth

Updated Category News Views 83

Supernus Pharmaceuticals Hits Record Stock Levels Supernus Pharmaceuticals Inc (NASDAQ: SUPN) has achieved a remarkable milestone, as its stock recently surged to a 52-week high of $35.45. This significant increase showcases the company’s strong financial performance and growth prospects, creating a wave of optimism among investors. The stock has risen an impressive...

Continue Reading